苯磺酸左旋氨氯地平联用脑复康治疗血管性痴呆的临床研究

目的:观察苯磺酸左旋氨氯地平联用脑复康治疗血管性痴呆(VD)的疗效。方法:将66例VD患者随机分为治疗组、对照组各33例。治疗组用苯磺酸左旋氨氯地平2·5～5mg,每日1次,脑复康0·8g,每日3次,共服3个月;对照组用脑复康0·8g,每日3次,共服3个月。其他根据血糖、血压、血脂相应基础治疗,观察3个月。治疗前、后用简易精神状态评估量表(MMSE)、日常生活功能量表(ADL)、长谷川痴呆量表(HDS)、痴呆严重程度临床评定量表(WMS),评价2组患者认知功能、智能状态。结果:治疗组用药后MMSE(22·48±3·25)分,ADL(25·16±8·96)分,HDS(23·14±2·91)分,WMS(71·14±19·01)分;对照组用药后MMSE(20·56±3·18)分,ADL(29·74±13·01)分,HDS(20·41±6·25)分,WMS(60·35±20·60)分。治疗组较对照组症状明显改善,差异有统计学意义(P<0·05或P<0·01)。结论:苯磺酸左旋氨氯地平联用脑复康,可明显改善患者的认知功能和智能状态,提高生活质量,治疗VD有效。

Clinical Study on Levoamlodipine Besylate Combined with Piracetam in the Treatment of Vascular Dementia

OBJECTIVE： To observe the efficacy of levoamlodipine besylate combined with piracetam for vascular dementia （VD）. METHODS： 66 patients with VD were enrolled： 33 （treatment group） were assigned to receive Levoamlodipine besylate 2.5-5 mg q.d plus piracetam 0.8 g tid for 3 months, and another 33 （control group） to receive piracetam 0.8 g tid plus basic treatment based on patients＇ blood glucose, blood pressure and blood lipid levels. The patients were given 3 - month follow- up. Mini- Mental State Examination （MMSE）, Activity of Daily Living Scale （ADL）, Hasegawa Dementia Scale （HDS） and Wechsler Memory Scale （WMS） were used to evaluate the patient＇ s cognitional function and mental state before and after treatment. RESULTS： MMSE, ADL, HDS, and WMS scores after treatment were （22.48±3.25）, （25.16±8.96）, （23.14±2.91）, （71.14±19.01）, respectively in treatment group versus （20.56±3.18）, （29.74±13.01）, （20.41±6.25）, （60.35±20.60）, respectively in control group. The treatment had a better improvement in symptoms than control group did and there was statistical difference between groups （P 〈 0.05 or P 〈 0.01）. CONCLUSION： Levamlodipine besylate combined with piracetam could significantly improve patient＇s cognitional function and mental state as well as patients＇ quality of life thus effective for VD.